Market Intelligence, Clinical Progress, and High-Purity Reagents for Cardiovascular and Neurological Disease Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for TRPC3 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Gene Delivery | TRPC3 Promise-ORF / Lentivirus Premade Particles. Full-length human TRPC3 for stable cell line generation. HEK293 Expressed (Native Glycosylation). Endotoxin Controlled. Sequence Verified. | View TRPC3 Products |
| Cloning Vector | TRPC3 Promise-ORF Mammalian Vector. Sequence Verified, C-terminal tags available. | View TRPC3 Products |
| Antigen | TRPC3 Extracellular Loop Reference Peptide / Membrane Preparation. For antibody generation and binding assays. High Purity (>95%). Sequence Verified. | View TRPC3 Products |
| Benchmark Ab | Anti-TRPC3 (Reference Sequence). Recombinant positive control for detection and assay development. | View TRPC3 Products |
| Validator | TRPC3 siRNA Set. For knockdown verification and specificity confirmation in calcium flux assays. HPLC purified (>95%), sequence confirmed by mass spectrometry. | View TRPC3 Products |
| Related Target A | TRPC6. Key paralog for selectivity counter-screening. Critical for subfamily off-target liability assessment and dual-target strategies. Forms functional heterotetramers with TRPC3. | View TRPC6 Products |
| Related Target B | TRPC7. Homolog for cross-reactivity assessment. | View TRPC7 Products |
| Related Target C | TRPC1. Heteromeric partner with TRPC3. Essential for studying native channel complexes and pathway modulation. | View TRPC1 Products |
| Related Target D | NFATc1. Downstream transcriptional effector of TRPC3-mediated calcium signaling. | View NFATc1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Selectivity vs TRPC6/TRPC7 subfamily (off-target toxicity risk) | Human TRPC3, TRPC6, TRPC7 Lentivirus Panel available. Sequence Verified ORFs with distinct epitope regions preserved. Enables direct counter-screening in identical cellular backgrounds. |
| Functional validation in native membrane conformation | Lentivirus Premade Particles deliver full-length TRPC3 to HEK293 cells. Preserves native glycosylation and tetrameric assembly for patch-clamp and calcium flux. |
| Cross-species cyno/mouse evaluation | Human / Mouse / Cynomolgus ortholog ORF clones with strict sequence verification (>95% purity at DNA level). |
| False positives / off-target pharmacology | Validated siRNA included for knockdown specificity checks. Confirms on-target ion channel modulation. |
| Lack of controls | Validated siRNA and reference antibodies provided for target knockdown and expression validation. |
Live TRPC3 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for TRPC3 therapeutics is intensifying as researchers uncover its critical role in pathological calcium signaling. The TRPC3 channel (Transient Receptor Potential Canonical 3) is a non-selective cation channel activated by diacylglycerol (DAG) downstream of Gq-coupled receptors. Historically, drug development has been challenging due to high homology within the TRPC family (especially TRPC6 and TRPC7, with >75% sequence identity in transmembrane regions). Major players such as GSK, Astellas, Sanofi, Kowa, and academic consortia have advanced programs from early pan-TRPC inhibitors to highly selective TRPC3 antagonists for neurological indications. As first-generation therapies face selectivity challenges and off-target toxicities (e.g., TRPC6-related nephrotoxicity), the next wave of R&D is targeting spinocerebellar ataxia (SCA), cardiac hypertrophy, fibrosis, and CNS disorders with modality-specific screening strategies. Allosteric modulators, state-dependent inhibitors, and BBB-penetrant scaffolds are emerging as next-generation approaches. Furthermore, dual TRPC3/6 inhibitors are being explored for renal and pulmonary fibrosis, while biologics (mAbs) targeting extracellular epitopes are enabled by cryo-EM structure determination.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Antagonist / Inhibitor | GSK, Astellas, Sanofi (Hydra), Kowa, Neuroscience-Focused Biotechs | Cardiac Hypertrophy, Cerebellar Ataxia (SCA), Anxiety Disorders, Fibrosis | Selectivity Assay (Need TRPC3 vs TRPC6/TRPC7 stable cell lines via Lentivirus) |
| Allosteric Modulator | Academic / Early-Stage Biotech Collaborations | Immune Modulation, Renal Disease | Conformational & Calcium Flux Assay (Need full-length TRPC3 in native membrane) |
| Gene Therapy / siRNA / ASO | Alnylam (preclinical), Early-stage Biotech | Spinocerebellar Ataxia, FSGS, Neurodegeneration | Knockdown Validation (Need sequence-verified siRNA and lentivirus for delivery) |
| Dual Inhibitors (TRPC3/6) | Preclinical pipelines | Renal & Pulmonary Fibrosis | Heteromeric Channel Assays (Need dual-expression cell lines) |
| Biologic (mAb) | Emerging Biotechs | Oncology (Immune modulation), CNS | Cell Surface Binding (Need full-length Lentivirus expression for screening) |
Key Genetic Mutations in TRPC3
A gain-of-function mutation in TRPC3 (SCA41) has been identified in patients with spinocerebellar ataxia. This mutation does not affect protein localization to the cell membrane but results in a toxic gain of function, likely through increased channel activity. This highlights the importance of selective inhibitors to counteract pathological calcium influx without affecting normal channel trafficking.